Hinokitiol (4-isopropyltropolone)

Hinokitiol (4-isopropyltropolone) is a natural tropolone compound extracted from the heartwood of Taiwanese hinoki cypress (Chamaecyparis taiwanensis) that exerts antimicrobial, anti-inflammatory, and anticancer effects primarily through iron chelation and SIRT1 pathway activation. Its seven-membered non-benzenoid aromatic ring enables unique metal-binding properties that disrupt iron-dependent bacterial and cancer cell metabolism.

Origin & History

Hinokitiol (4-isopropyltropolone) is a natural monoterpenoid belonging to the tropolone chemical class, isolated from the heartwood of trees in the Cupressaceae family, including Chamaecyparis obtusa, Thuja plicata, and Calocedrus formosana. It occurs naturally in these plants and is typically extracted from the trunk or wood via solvent methods.

Historical & Cultural Context

No specific historical or traditional medicinal uses are documented in the available research. Hinokitiol is primarily described as a natural compound from Cupressaceae trees without reference to traditional medicine systems.

Health Benefits

• Anti-cancer properties: Shows dose-dependent viability suppression, cell cycle arrest, and apoptosis induction in cervical, breast, and lung cancer cell lines (preliminary in vitro evidence)
• Anti-inflammatory effects: Inhibits proinflammatory factors (TNF-α, IL-6, PGE2) via SIRT1 activation (preliminary in vitro evidence)
• Cancer stem cell inhibition: Reduces stemness markers (CD44, SOX2, Oct4, Nanog) in breast cancer cells at 50 μM (preliminary in vitro evidence)
• Migration inhibition: Blocks cancer cell migration at 1-5 μM in lung adenocarcinoma cells without affecting viability (preliminary in vitro evidence)
• Iron redistribution: Demonstrated ability to redistribute iron from liver to red blood cells in ferroportin-deficient mice models (preliminary animal evidence)

How It Works

Hinokitiol chelates ferric iron (Fe³⁺) via its tropolone ring structure, disrupting iron-dependent enzymatic processes in bacteria and cancer cells including ribonucleotide reductase activity essential for DNA synthesis. It activates SIRT1 (Sirtuin-1), a NAD⁺-dependent deacetylase, which downregulates NF-κB signaling and reduces transcription of proinflammatory mediators including TNF-α, IL-6, and COX-2-derived PGE2. In cancer cell lines, it induces G1/S or G2/M cell cycle arrest through modulation of cyclin-dependent kinase inhibitors such as p21 and p27, while simultaneously activating intrinsic apoptotic pathways via caspase-3 and caspase-9 cleavage.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses have been conducted with hinokitiol. All available evidence is limited to preclinical in vitro studies using cancer cell lines and animal models, with concentrations ranging from 1-200 μM showing various anticancer and anti-inflammatory effects.

Clinical Summary

The majority of hinokitiol research consists of in vitro cell culture studies and rodent models, with no published large-scale randomized controlled trials in humans as of 2024. In vitro studies on cervical (HeLa), breast (MCF-7), and lung (A549) cancer cell lines demonstrate dose-dependent viability suppression at concentrations ranging from 10–100 µM, though translating these concentrations to human dosing remains unestablished. Anti-inflammatory effects were characterized in LPS-stimulated macrophage models showing significant reduction of TNF-α and IL-6 at low micromolar concentrations via SIRT1 activation. Topical formulations containing 0.1–0.5% hinokitiol have been evaluated in small dermatological studies for acne and seborrheic conditions, showing tolerability, but sample sizes were typically under 50 participants, limiting conclusions.

Nutritional Profile

{"macronutrients": {"protein": "Not applicable", "fiber": "Not applicable", "fats": "Not applicable", "carbohydrates": "Not applicable"}, "micronutrients": {"vitamins": "Not applicable", "minerals": "Not applicable"}, "bioactive_compounds": {"hinokitiol": "Concentration varies depending on the source, typically found in trace amounts in natural sources like the heartwood of the Hinoki tree.", "bioavailability_notes": "Hinokitiol has moderate bioavailability, and its absorption can be influenced by the formulation and delivery method."}}

Preparation & Dosage

No clinically studied dosages exist due to absence of human trials. In vitro studies use 1-5 μM for migration inhibition, 50 μM for stemness/apoptosis effects, and up to 200 μM for viability studies. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, EGCG, Curcumin, Resveratrol, Vitamin C

Safety & Interactions

Hinokitiol is generally regarded as safe at low concentrations used in approved cosmetic and oral care products (typically 0.1–1%), with a long history of use in Japanese consumer products. At higher experimental doses, iron-chelating activity poses a theoretical risk of interfering with dietary iron absorption or iron-dependent medications, and caution is warranted in individuals with anemia or iron-deficiency conditions. Due to its iron-chelating mechanism, concurrent use with iron supplements or deferoxamine-class chelators may produce additive or antagonistic effects, though human pharmacokinetic interaction data are absent. Pregnancy and lactation safety has not been established in clinical studies, and use beyond topical cosmetic concentrations is not recommended during pregnancy.